SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility after a rapid price surge and subsequent collapse, sparking widespread accusations of a pump-and-dump scheme and market manipulation. Community sentiment is deeply polarized, with some traders hunting for dip-buying opportunities and potential recovery rallies, while others warn of a textbook rug pull and significant losses for retail investors.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is generating intense social media hype as traders debate whether the asset is a legitimate moonshot or a speculative bubble prone to volatility. The community is actively discussing the coin's rapid price action and its potential influence on current market trends surrounding emerging community-driven tokens.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to activist investor Shah Capital's aggressive push for management accountability, including demands for a board reduction and share buybacks, while the community remains divided over the company's progress on partnership timelines and oncology initiatives.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing intense community focus ahead of the scheduled Sunday launch of its BlueBird 7 satellite, which investors view as a critical validation of the company's direct-to-device connectivity thesis. While shareholders are actively discussing recent institutional share sales and price volatility, the conversation remains largely focused on the long-term potential of the constellation's build-out and the upcoming deployment of larger satellite arrays.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan is currently in the spotlight as investors parse mixed signals from leadership regarding long-term resilience versus looming geopolitical and credit risks. The community is actively debating the stock's role as a financial bellwether, with sentiment divided between those betting on institutional strength and those highlighting potential exposure to private credit vulnerabilities.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently experiencing a divergence in market sentiment as it navigates a key consolidation zone, with traders weighing institutional accumulation and upcoming regulatory catalysts against ongoing geopolitical uncertainty regarding shipping routes. The community remains polarized, actively debating whether the asset is poised for a structural breakout fueled by potential legislative progress or if it will continue to underperform compared to other parts of the crypto ecosystem.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing extreme volatility driven by speculative momentum surrounding a potential executive order to expedite ibogaine research for veteran mental health treatments. The community is heavily polarized, with bulls betting on a short squeeze due to the stock's low float and pending news, while bears argue the move is a classic pump-and-dump event driven by over-leveraged sentiment.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant momentum driven by positive clinical data from its siRNA pipeline, which has renewed investor confidence in the company's long-term rare disease strategy. The community is actively debating the stock's future, balancing the promising early-stage results against regulatory headwinds and persistent short interest.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The IWM is experiencing significant volatility as market participants fixate on geopolitical tensions in the Middle East and the potential for a naval blockade in the Strait of Hormuz. While some investors are betting on a parabolic rally driven by peace deal optimism and FED liquidity, others remain highly skeptical, cautioning that broader macroeconomic risks and overbought technical conditions could trigger a sharp reversal.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending as investors weigh its potential as a critical infrastructure provider for personalized cancer vaccines and immunotherapies, even as they navigate a competitive landscape filled with recent sector acquisitions. While community sentiment remains focused on the company's ultra-sensitive MRD technology and potential Medicare reimbursement catalysts, discussions highlight a divide between those tracking the long-term strategic value of the platform and those frustrated by current communication and commercial execution timelines.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors.</li><li>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for gross proceeds up to approximately $354 million.&nbsp;</li><li>Achieve is now looking forward to launching cytisinicline for nicotine dependence in the first half of 2027.</li></ul><p><br>Shares of Achieve Life Sciences Inc. (ACHV) gained 42% on Thursday after the company appointed a new CEO, shortly after announcing a private placement of up to $354 million, as it gears towards getting regulatory approval for its experimental drug for the treatment of nicotine dependence.</p><p>The stock is on track to clock its best day since February 2019, if gains hold.</p><h2 class="st-heading-2">New CEO, Board Appointments</h2><p>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors. Goldberg, who most recently served as a Portfolio Manager at Marshall Wace, will replace Richard Stewart as CEO.</p><p>The company also appointed Lucian Iancovici and Aaron E. Royston as members of the company’s board of directors.</p><h2 class="st-heading-2">Fresh Funding</h2><p>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities.</p><p>The placement includes an initial upfront funding of approximately $180 million and an additional amount of up to approximately $174 million on exercise of milestone-driven warrants. The net proceeds from the placement is expected to fund a clinical trial for cytisinicline for e-cigarette cessation, the commercialization of cytisinicline, and for working capital and general corporate purposes, the company said.</p><h2 class="st-heading-2">Near-Term Milestones</h2><p>Achieve is now looking forward to the U.S. Food and Drug Administration’s approval of cytisinicline as a treatment for nicotine dependence.</p><p>Earlier this week, the company said that it expects the FDA to reject its current application by June 20, provided that the agency found manufacturing concerns at its third-party manufacturing facility. Once the formal rejection is received, the company expects to resubmit its application naming &nbsp;Adare Pharma Solutions as its manufacturer for commercial supply in the fourth quarter of 2026, it said. The company continues to expect to launch cytisinicline in the first half of 2027.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ACHV stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.</p><p>A Stocktwits user expressed optimism for the company getting acquired after approval for cytisinicline.</p><p><stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/650482761</stembedurl></p><p>Another user expressed optimism for a good year following the “professional” announcements.</p><p><stembedurl>https://www.stocktwits.com/Sieppo/message/650471510</stembedurl></p><p><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has more than doubled over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hubc-stock-tanks-after-massive-rally-reverse-split/cZJvo99RIDA">HUBC Stock Declines 35% After A Whopping Two-Day Rally – What’s Driving The Change In Momentum?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 

Equity

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 


Achieve Life Sciences' (ACHV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm...

What is Zacks Research's Estimate for ACHV FY2026 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Zacks Research dropped their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on...

HC Wainwright Has Positive Estimate for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings estimates for shares of Achieve Life Sciences in a research report issued...

Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med

Achieve Life Sciences taps Adare for cytisinicline manufacturing as stock falls; reports wider losses and shifts US launch timeline to 2027.read more...

Q1 Earnings Estimate for ACHV Issued By HC Wainwright

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Achieve Life Sciences in a research report...

HC Wainwright Reiterates "Buy" Rating for Achieve Life Sciences (NASDAQ:ACHV)

HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Achieve Life Sciences in a research report on Wednesday...

Achieve Life Sciences Sees Unusually Large Options Volume (NASDAQ:ACHV)

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 2,079 call options on the company. This represents an increase of approximately 175% compared to the typical daily volume of 756 call options...

Achieve Life Sciences Q4 Earnings Call Highlights

Achieve Life Sciences (NASDAQ:ACHV) used its fourth-quarter and full-year 2025 earnings call to outline progress toward a potential U.S. launch of cytisinicline, the company's investigational therapy...

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ACHV News

ACHVAchieve Life Sciences Inc.